Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?

Author(s): Steven C. Bharadwaj, Alexander S. Farivar

Journal Name: Current Respiratory Medicine Reviews

Volume 8 , Issue 4 , 2012

Become EABM
Become Reviewer
Call for Editor


Malignant pleural mesothelioma (MPM) is an aggressive malignancy. It most frequently develops following occupational exposure to asbestos, a highly flame-retardant material used in construction. The delay between exposure and development of MPM ranges from 25-50 years and therefore most patients present in the 5th to 7th decade of life. MPM can present like many other common pleural diseases therefore diagnosis requires clinical acumen. Tissue sampling is required with best results from directed pleural biopsy.

Once a diagnosis of MPM has been made, treatment depends upon the stage of disease, histological diagnosis and performance status of the patient. Palliation is reserved for patients with multiple comorbidities that are unlikely to withstand aggressive treatment or patients with advanced disease involving the peritoneum or contralateral hemithorax. Those presenting with epithelial histology, earlier stage and good performance status are candidates for multimodality therapy. Case series report long term survival in patients treated with a trimodality approach involving chemotherapy, surgery and radiation. Our approach is to carefully select patients by thoroughly evaluating patient’s physiological status and clinical stage of disease before embarking on induction chemotherapy, extrapleural pneumonectomy and postoperative radiotherapy. By utilizing this paradigm we report outcomes similar to other expert groups treating this aggressive malignancy. In order to improve upon outcomes, novel chemotherapeutic targets need to be identified. Molecular biological techniques are uncovering potential mediators in the carcinogenesis of MPM.

Keywords: Asbestos, chemotherapy, extrapleural pneumonectomy, IMRT, Malignant pleural mesothelioma, palliation, pleurectomy/decortication, trimodality therapy, pleural biopsy, peritoneum or contralateral hemithorax.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [304 - 313]
Pages: 10
DOI: 10.2174/157339812802652143
Price: $65

Article Metrics

PDF: 4